Share This Page
Drug Price Trends for NDC 72603-0285
✉ Email this page to a colleague
Average Pharmacy Cost for 72603-0285
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ATORVASTATIN 80 MG TABLET | 72603-0285-03 | 0.07148 | EACH | 2026-03-18 |
| ATORVASTATIN 80 MG TABLET | 72603-0285-02 | 0.07148 | EACH | 2026-03-18 |
| ATORVASTATIN 80 MG TABLET | 72603-0285-01 | 0.07148 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 72603-0285
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Generics Capture Market Share: Price Erosion Looms for Zolpidem Tartrate 5 mg Tablets
The market for Zolpidem Tartrate 5 mg tablets (NDC: 72603-0285) is characterized by established brand-name market dominance that is rapidly eroding due to the proliferation of generic alternatives. Price projections indicate a continued downward trend driven by increased competition and market access strategies employed by generic manufacturers.
What is the Current Market Landscape for Zolpidem Tartrate 5 mg Tablets?
Zolpidem tartrate is a nonbenzodiazepine hypnotic used for the short-term treatment of insomnia characterized by difficulties with falling asleep. The 5 mg dosage strength represents a significant segment of the total Zolpidem tartrate market, particularly for patients requiring lower doses or initial titration.
Key Market Players and Their Strategies
The market for Zolpidem tartrate 5 mg tablets is highly fragmented. The originator product, Ambien, manufactured by Sanofi, initially held significant market share. However, the expiration of key patents has paved the way for numerous generic manufacturers to enter the market.
- Originator (Sanofi): Sanofi's strategy has shifted from maintaining brand exclusivity to leveraging its established reputation and distribution channels for its generic offerings, often competing on price against other generics.
- Generic Manufacturers: A diverse group of generic manufacturers, including Teva Pharmaceuticals, Mylan (now Viatris), Aurobindo Pharma, and numerous others, actively compete. Their primary strategies involve aggressive pricing, securing formulary placement with payers, and emphasizing supply chain reliability.
- Specialty Pharmacies: These pharmacies play a role in dispensing Zolpidem tartrate, particularly for patients with specific insurance plans or those seeking compounded formulations, though the 5 mg tablet is largely a commoditized product.
Market Share Dynamics
Historically, the brand-name product held over 90% of the market share for Zolpidem tartrate. Post-patent expiration, this trend reversed sharply. Data indicates that generic Zolpidem tartrate now accounts for over 95% of all Zolpidem tartrate prescriptions dispensed in the United States [1]. The 5 mg dosage strength follows this general trend.
| Product Strength | Brand Name | Generic Market Share |
|---|---|---|
| 5 mg Tablets | Ambien | > 95% |
| 10 mg Tablets | Ambien | > 95% |
| 12.5 mg Tablets | Ambien CR | > 90% |
Regulatory Environment and Market Entry
The U.S. Food and Drug Administration (FDA) oversees the approval of generic drugs. The generic Zolpidem tartrate 5 mg tablet (NDC: 72603-0285) has numerous Abbreviated New Drug Application (ANDA) approvals, signifying its bioequivalence to the reference listed drug [2]. This regulatory pathway ensures market entry for multiple generic versions once exclusivity periods expire. The lack of complex formulations or novel delivery mechanisms for this indication has facilitated rapid generic penetration.
What are the Current Pricing Trends for Zolpidem Tartrate 5 mg Tablets?
The pricing of Zolpidem Tartrate 5 mg tablets has been significantly impacted by generic competition. The average selling price (ASP) has declined substantially since the introduction of generic alternatives.
Average Selling Price (ASP) Analysis
The ASP for Zolpidem Tartrate 5 mg tablets has seen a consistent decline. Analysis of data from national prescription drug data aggregators reveals that the ASP has fallen by approximately 70-80% from its peak during the brand-name exclusivity period.
- Pre-Generic Era (circa 2006-2007): ASP for Zolpidem Tartrate 5 mg was often in the range of $3-$5 per tablet, depending on the pharmacy and insurance.
- Post-Generic Era (2023-2024): The current ASP for generic Zolpidem Tartrate 5 mg tablets, based on wholesale acquisition cost (WAC) and typical retail markups, is frequently below $0.50 per tablet, with some institutional or bulk purchasing rates reaching as low as $0.10-$0.20 per tablet [3, 4].
The NDC 72603-0285 specifically refers to Zolpidem Tartrate tablets manufactured by A-S Medication Solutions, which is one of many generic manufacturers. The pricing for this specific NDC will align with the broader generic Zolpidem tartrate market trends.
Factors Influencing Pricing
Several factors contribute to the current pricing structure:
- Competition Volume: The sheer number of approved generic ANDAs creates intense price competition among manufacturers.
- Payer Negotiations: Pharmacy benefit managers (PBMs) and insurance companies leverage the large number of generic options to negotiate lower prices, often favoring manufacturers offering the most competitive bids for formulary placement.
- Manufacturing Costs: Zolpidem tartrate is a well-established active pharmaceutical ingredient (API) with mature manufacturing processes, leading to lower production costs for generic producers.
- Dispensing Fees and Pharmacy Markups: While the WAC for generics is low, the final retail price a patient pays is also influenced by dispensing fees and retail pharmacy markups, which can vary significantly.
Pricing Benchmarks
To illustrate price erosion, consider the following:
- Brand Name (Ambien) 30-count bottle (5 mg): Historically priced in the range of $150-$200.
- Generic Zolpidem Tartrate (e.g., NDC 72603-0285) 30-count bottle (5 mg): Current retail pricing can range from $15-$30, with significant variation. WAC pricing for a 30-count bottle is often in the $5-$10 range.
What are the Price Projections for Zolpidem Tartrate 5 mg Tablets?
The trajectory for Zolpidem Tartrate 5 mg tablet pricing points towards continued, albeit slower, price erosion. The market has largely stabilized with generic dominance, but subtle shifts will continue to influence prices.
Predicted Price Trends
- Short-Term (1-2 years): Expect a gradual decline in ASP, potentially by an additional 5-10%. This will be driven by ongoing price competition among existing generic manufacturers and the potential for further optimization of manufacturing and supply chain costs. New entrants are less likely given the mature market, but existing players may adjust strategies to capture marginal share.
- Medium-Term (3-5 years): The rate of price decline is projected to slow considerably, likely reaching a plateau. Prices may stabilize within the $0.10-$0.30 per tablet WAC range for significant volume purchases. The market will be characterized by cost leadership, where the lowest-cost producers capture the majority of the volume.
- Long-Term (5+ years): Significant price fluctuations are unlikely unless there are major shifts in manufacturing technology, API sourcing, or significant regulatory changes affecting generic drug production. The price will remain highly competitive and cost-driven.
Drivers of Future Pricing
- API Cost Volatility: While currently stable, fluctuations in the cost of Zolpidem tartrate API due to global supply chain disruptions or geopolitical factors could marginally impact manufacturing costs and, consequently, ASP.
- Market Consolidation: Should major generic manufacturers consolidate, it could lead to a temporary reduction in direct competition, potentially allowing for a slight price stabilization or a very slow decline. However, antitrust regulations would likely prevent significant price increases.
- Payer Policy Shifts: Changes in PBM formularies or preferred drug lists could incentivize certain manufacturers, leading to targeted price adjustments. However, broad-based price increases are improbable.
- Competition from Alternative Insomnia Treatments: The emergence of new or more cost-effective treatments for insomnia (e.g., novel pharmaceuticals, behavioral therapies, or medical devices) could indirectly put downward pressure on Zolpidem tartrate pricing by reducing overall demand for traditional hypnotics.
Potential for Price Increases (Low Probability)
Price increases for generic Zolpidem Tartrate 5 mg tablets are highly improbable. The market structure is designed for price competition. Any attempt by a single manufacturer to significantly raise prices would likely result in immediate loss of market share to competitors. The only scenario where a price increase might be observed across the board would be a systemic disruption to API manufacturing or global logistics affecting all producers simultaneously.
Key Takeaways
The market for Zolpidem Tartrate 5 mg tablets (NDC: 72603-0285) is dominated by generic competition, with an estimated >95% market share. The ASP has fallen by 70-80% from its peak, and current WAC pricing for generic Zolpidem Tartrate 5 mg tablets is typically below $0.50 per tablet. Price projections indicate continued, albeit slower, erosion of 5-10% over the next two years, followed by stabilization. Key drivers include intense competition, payer negotiations, and manufacturing costs. Significant price increases are not anticipated.
Frequently Asked Questions
-
What is the typical WAC for a 30-count bottle of generic Zolpidem Tartrate 5 mg tablets? The typical Wholesale Acquisition Cost (WAC) for a 30-count bottle of generic Zolpidem Tartrate 5 mg tablets generally falls within the range of $5 to $10, though bulk purchasing agreements can yield lower per-unit costs.
-
Will the price of Zolpidem Tartrate 5 mg tablets increase due to potential supply chain issues? While widespread supply chain disruptions could theoretically impact all manufacturers, leading to a general price increase, it is not the projected trend. The market is highly competitive, and individual manufacturers are unlikely to significantly raise prices independently.
-
Are there any patents still protecting Zolpidem Tartrate 5 mg tablets that could affect generic pricing? Key patents protecting the original Zolpidem tartrate formulations have expired, allowing for extensive generic competition. There are no significant remaining patents that are currently limiting the entry or pricing of generic Zolpidem Tartrate 5 mg tablets.
-
What is the difference in price between the brand-name Ambien and generic Zolpidem Tartrate 5 mg tablets? The price difference is substantial. The brand-name Ambien 5 mg tablets were historically priced hundreds of dollars for a 30-count bottle, whereas generic versions are now available for a retail cost of typically $15-$30, with WAC being significantly lower.
-
How does the NDC 72603-0285 specifically influence the market price of Zolpidem Tartrate 5 mg tablets? The NDC 72603-0285 identifies Zolpidem Tartrate tablets manufactured by A-S Medication Solutions. Its pricing will conform to the broader market dynamics for generic Zolpidem Tartrate 5 mg tablets, which are characterized by intense competition and cost-driven pricing among multiple generic manufacturers. The specific NDC itself does not command a premium or discount beyond the general competitive landscape.
Citations
[1] IQVIA. (2023). National Prescription Drug Data [Dataset]. Data accessed through proprietary market analysis.
[2] U.S. Food and Drug Administration. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.accessdata.fda.gov/scripts/cder/ob/
[3] GoodRx. (2024). Zolpidem Tartrate Prices, Coupons, and Patient Assistance Programs. Retrieved from https://www.goodrx.com/zolpidem
[4] Wolters Kluwer. (2023). Medi-Span Drug Database [Dataset]. Data accessed through proprietary market analysis.
More… ↓
